Ammonia Market worth $91.95 billion by 2029, at 3.0%, says MarketsandMarkets™
Delray Beach, FL, April 15, 2025 (GLOBE NEWSWIRE) -- In terms of value, the Ammonia Market size is projected to grow from USD 79.47 billion in 2024 and is projected to reach USD 91.95 billion by 2029, at a CAGR of 3.0%, as per the recent study by MarketsandMarkets™. The ammonia market is predicted to rise steadily throughout the forecast period, owing to ammonia being an essential component in agriculture as a key ingredient fertilizer. Globally as the population is increasing consequently there will be a high demand for higher crop yields, this will increase the demand for ammonia as it boosts the soil productivity. Governments across the globe are investing in greener energy solutions and adopting stricter environmental regulations.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=252376175
Browse in-depth TOC on 'Ammonia Market'
225 - Market Data Tables 54 – Figures 231 - Pages
List of Key Players in Ammonia Market:
CF Industries Holdings, Inc. (US),
Yara International ASA (Norway),
OCI Global (Netherlands),
BASF SE (Germany),
Nutrien (Canada).
Drivers, Opportunities and Challenges in Ammonia Market:
Drivers: Rising agricultural demand for ammonia
Restraint: Fluctuations in pricing
Opportunity: Growing emphasis on low-carbon solutions
Challenge: Alternative technologies
Get Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=252376175
Key Findings of the Study:
By type, anhydrous accounts for the largest share of the ammonia market.
Textile accounts for the second-largest share of the ammonia market by end-use industry.
Europe accounted for the second largest share in the global ammonia market.
The ammonia market is segmented into two types, anhydrous, and aqueous. Anhydrous type of ammonia is projected to grow at a faster rate during the forecast period. This growth is attributed to its cost-effectiveness and direct application to soil. Anhydrous ammonia is preferred by farmers for large-scale agricultural enterprises. Its utilization is also increasing due to the necessity for efficient farming methods and the growing demand for food. Anhydrous ammonia's demand in the market is being driven by its increasing attention in industrial applications and as a fuel in the shift to clean energy.
Based on sales channels, the ammonia market is segmented into direct and indirect. Large-scale customers including industrial buyers and farmers prefer direct sales to ensure steady, large-scale ammonia supply at competitive rates. Direct communication between producers and consumers promotes operational efficiency through higher customization, higher-quality products, and prompt delivery. Thus, direct sales are anticipated to become significant in the ammonia market.
Get Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=252376175
By end-use industry ammonia market is segmented into agriculture, textile, refrigeration, mining, pharmaceutical, and other end-use industries. The agriculture is expected to dominate the ammonia market during the forecast period. The demand for effective farming methods increases with population growth, which increases the need for ammonia for producing fertilizers like urea and ammonium nitrate. Ammonia's use in this industry is further boosted by the government's support for increasing agricultural output and the growing use of advanced farming practices.
Based on region the ammonia market is segmented into five regions, namely, North America, Asia Pacific, Europe, Middle East & Africa, and South America. Asia Pacific accounted for the largest share of the ammonia market in 2023. In countries like China, and India, the need to feed a growing population is driving the agricultural sector in Asia Pacific which will further propel the ammonia market. Ammonia production and consumption are also rising because of investments in renewable energy sources, growing chemical manufacturing, and industrial growth in the Asia Pacific. Ammonia is also increasing in Asia Pacific due to its availability of raw materials and lower manufacturing costs
Browse Adjacent Markets Bulk Chemicals & Inorganics Research Reports
Related Reports:
Data Canter Liquid Cooling Companies
Ammonia Companies
Bioplastics Companies
Centrifuge Companies
Decorative Concrete Companies
CONTACT: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Rohan Salgarkar MarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445, USA: +1-888-600-6441 Email: sales@marketsandmarkets.com Visit Our Website: www.marketsandmarkets.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
an hour ago
- Wall Street Journal
Asian Currencies Consolidate as Traders Assess U.S.-China Agreement
0117 GMT — Asian currencies consolidate against the dollar in the morning session as traders assess the U.S.-China agreement on a framework to ease trade tensions. Representatives from the two countries said the framework would essentially restore a pact they agreed to in Switzerland last month, a deal that saw both sides reduce tariffs. However, the negotiators refrained from disclosing exactly what they had agreed to as part of the framework, which may result in continued uncertainty over the trade truce. USD/JPY is steady at 144.91; USD/KRW edges 0.1% lower to 1,364.40; AUD/USD is 0.1% lower at 0.6519. (
Yahoo
2 hours ago
- Yahoo
Global Uranium Corp. Announces LIFE Offering for up to C$1,500,000
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | FRA: Q3J) (the 'Company') is pleased to announce that it intends to complete a non-brokered private placement financing (the 'Offering') of a minimum of 1,666,666 units of the Company (each, a 'Unit') and a maximum of 10,000,000 Units, at a price of C$0.15 per Unit, for gross minimum proceeds of C$250,000 and gross maximum proceeds of C$1,500,000. Each Unit shall be comprised of one common share in the capital of the Company (each, a 'Share') and one Share purchase warrant ('Warrant'), with each Warrant entitling the holder to purchase one Share at a price of C$0.20 for a period of 24 months from Closing (as defined herein). Closing of the Offering is anticipated to occur on or about July 25, 2025 ('Closing'), subject to the satisfaction of certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. The net proceeds of the Offering are intended to be used for exploration activities, for general administrative expenditures, and for general working capital purposes. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions ('NI 45-106'), the securities issuable under the Offering will be offered for sale to purchasers resident in all of the provinces of Canada (except Quebec) pursuant to the listed issuer financing exemption under Part 5A.2 of NI 45-106 (the 'LIFE Exemption'). As such, the securities issued to subscribers will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an offering document dated June 10, 2025 related to the Offering that can be accessed under the Company's profile at and on the Company's website at This offering document contains additional detail regarding the Offering, including additional detail regarding the expected use of proceeds therefrom. Prospective investors in the Offering should read this offering document before making an investment decision. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any available exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. ABOUT GLOBAL URANIUM CORP. Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America. The Company currently holds key uranium projects: the Wing Lake Property in the Mudjatik Domain of Northern Saskatchewan, Canada; the Northwest Athabasca Joint Venture with Forum Energy Metals Corp. and NexGen Energy Ltd. in the Northwest Athabasca region of Saskatchewan, Canada; the Astro Uranium Project with Cosa Resources Corp in the eastern Athabasca Basin, Saskatchewan; and the Great Divide Basin District Projects, the Gas Hills District Projects, and the Copper Mountain District Projects in Wyoming, USA. ON BEHALF OF THE BOARD OF DIRECTORSUngad ChaddaCEO 587-330-0045info@ FORWARD-LOOKING STATEMENTS Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words 'could', 'intend', 'expect', 'believe', 'will', 'projected', 'estimated' and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. In particular, this press release contains forward-looking information relating to, among other things, the Offering, including the total anticipated proceeds, the expected use of proceeds, and the closing (including the proposed closing date) of the Offering. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information, including the assumption that the Company will close the Offering on the timeline anticipated, will raise the anticipated amount of gross proceeds from the Offering and will use the proceeds of the Offering as anticipated. Those assumptions and factors are based on information currently available to the Company. Although such statements are based on reasonable assumptions of the Company's management, there can be no assurance that any conclusions or forecasts will prove to be accurate. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include: the risk that the Offering does not close on the timeline expected, or at all; the risk that the Company raises less than the anticipated amount of gross proceeds from the Offering; the risk that the Company does not use the proceeds from the Offering as currently expected; risks inherent in the exploration and development of mineral deposits, including risks relating to receiving requisite permits and approvals, changes in project parameters or delays as plans continue to be redefined, that mineral exploration is inherently uncertain and that the results of mineral exploration may not be indicative of the actual geology or mineralization of a project; that mineral exploration may be unsuccessful or fail to achieve the results anticipated by the Company; operational risks; regulatory risks, including risks relating to the acquisition of the necessary licenses and permits; financing, capitalization and liquidity risks; title and environmental risks; and risks relating to the failure to receive all requisite regulatory approvals. The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this press release.Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., June 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on June 10, 2025, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 115,620 shares of common stock and 57,740 restricted stock units ("RSUs") to 10 new employees under Mirum's 2020 Inducement Plan. The Compensation Committee of Mirum's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $48.98 per share, Mirum's closing trading price on June 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees' continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum's 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder. To learn more about Mirum, visit and follow Mirum on Facebook, LinkedIn, Instagram and X. View source version on Contacts Investor Contact: Andrew McKibbenir@ Media Contact: Erin Murphymedia@ Sign in to access your portfolio
